BR112017007773A2 - novos peptídeos imunogênicos - Google Patents

novos peptídeos imunogênicos

Info

Publication number
BR112017007773A2
BR112017007773A2 BR112017007773-6A BR112017007773A BR112017007773A2 BR 112017007773 A2 BR112017007773 A2 BR 112017007773A2 BR 112017007773 A BR112017007773 A BR 112017007773A BR 112017007773 A2 BR112017007773 A2 BR 112017007773A2
Authority
BR
Brazil
Prior art keywords
immunogenic peptides
new immunogenic
cst
new
epitope
Prior art date
Application number
BR112017007773-6A
Other languages
English (en)
Inventor
Saint-Remy Jean-Marie
Carlier Vincent
Vander Elst Luc
Burkhart David
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of BR112017007773A2 publication Critical patent/BR112017007773A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a invenção refere-se aos peptídeos imunogênicos isolados, compreendendo um epítopo de célula t do mhc classe ii, e imediatamente adjacente ou separada do dito epítopo, uma porção redox h-x(0,2)-c-x(2)-[cst] ou [cst]-x(2)-c-x(0,2)-h.
BR112017007773-6A 2014-10-17 2015-10-16 novos peptídeos imunogênicos BR112017007773A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1418433.7A GB201418433D0 (en) 2014-10-17 2014-10-17 Novel immunogenic peptides
GB1418433.7 2014-10-17
PCT/EP2015/074063 WO2016059236A1 (en) 2014-10-17 2015-10-16 Novel immunogenic peptides

Publications (1)

Publication Number Publication Date
BR112017007773A2 true BR112017007773A2 (pt) 2018-01-16

Family

ID=52013133

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007773-6A BR112017007773A2 (pt) 2014-10-17 2015-10-16 novos peptídeos imunogênicos

Country Status (16)

Country Link
US (2) US20180228912A1 (pt)
EP (2) EP3636666A1 (pt)
JP (2) JP6655626B2 (pt)
KR (1) KR102556485B1 (pt)
CN (1) CN107148427B (pt)
AU (2) AU2015332621B2 (pt)
BR (1) BR112017007773A2 (pt)
CA (1) CA2964426C (pt)
DK (1) DK3207053T3 (pt)
ES (1) ES2751605T3 (pt)
GB (1) GB201418433D0 (pt)
MX (1) MX2017004780A (pt)
PL (1) PL3207053T3 (pt)
PT (1) PT3207053T (pt)
RU (1) RU2709711C2 (pt)
WO (1) WO2016059236A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5750600B2 (ja) 2006-08-11 2015-07-22 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルクＬｉｆｅ Ｓｃｉｅｎｃｅｓ Ｒｅｓｅａｒｃｈ Ｐａｒｔｎｅｒｓ Ｖｚｗ 免疫原性ペプチドおよび免疫障害におけるその使用
EP2244733B1 (en) 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
ES2676630T3 (es) 2008-02-14 2018-07-23 Life Sciences Research Partners Vzw Control inmunogénico de tumores y células tumorales
JP6173915B2 (ja) 2010-11-25 2017-08-02 イムナテ・ソシエテ・ア・レスポンサビリテ・リミテＩｍｎａｔｅ Ｓａｒｌ 感染症、自己免疫疾患、同種因子に対する免疫応答、アレルギー性疾患、腫瘍、移植片拒絶反応、および、遺伝子療法または遺伝子ワクチン接種のために使用されるウイルスベクターに対する免疫応答の予防および／または治療における使用のための免疫原性ペプチド
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
US10653797B2 (en) 2015-09-02 2020-05-19 Sanford Burnham Prebys Medical Discovery Institute Compounds and compositions for targeting brain injuries and methods of use thereof
AU2016328582B2 (en) 2015-09-25 2022-11-24 Imcyse Sa Improved methods and compounds for eliminating immune responses to therapeutic agents
RU2018136760A (ru) * 2016-04-19 2020-05-19 Имсис Са НОВЫЕ ИММУНОГЕННЫЕ CD1d-СВЯЗЫВАЮЩИЕ ПЕПТИДЫ
CU24596B1 (es) * 2017-03-09 2022-05-11 Imcyse Sa Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes
EP3720503A4 (en) 2017-12-07 2021-09-08 Sanford Burnham Prebys Medical Discovery Institute COMPOSITIONS AND METHODS OF TREATMENT OF LESIONS OF THE NERVOUS SYSTEM
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
CA3138713A1 (en) 2019-05-16 2020-11-19 Imcyse Sa Immunogenic peptides with an oxidoreductase motif comprising a modified cysteine
US20230136112A1 (en) 2019-11-27 2023-05-04 Imcyse Sa Methods for stratifying diabetes patients
EP4146676A2 (en) 2020-05-06 2023-03-15 Imcyse SA Peptides and methods for the treatment of multiple sclerosis
US20230172894A1 (en) * 2020-05-06 2023-06-08 Imcyse Sa Combination treatment for fumarate-related diseases
EP4146255A1 (en) 2020-05-06 2023-03-15 Imcyse SA Immunogenic peptides with new oxidoreductase motifs
CN115916805A (zh) 2020-05-06 2023-04-04 易姆赛斯股份公司 具有延伸的氧化还原酶基序的免疫原性肽
EP3915575A1 (en) * 2020-05-29 2021-12-01 Imnate Sarl Vaccine formulations
US20240150407A1 (en) * 2021-04-09 2024-05-09 Ajou University Industry-Academic Cooperation Foundation Peptide for preventing or treating inflammatory diseases
JP2024520030A (ja) 2021-05-26 2024-05-21 アンシス・エスア 自己免疫疾患を処置又は予防する方法
AU2022286630A1 (en) 2021-06-01 2023-12-07 Imcyse Sa Improved methods of treatment using immunogenic peptides
WO2022256637A2 (en) * 2021-06-03 2022-12-08 David Weiner Synthetic dna vaccine immunogenic improvements
AR126654A1 (es) 2021-06-29 2023-11-01 Imcyse Sa Péptidos y métodos para el tratamiento de neuromielitis óptica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5750600B2 (ja) * 2006-08-11 2015-07-22 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルクＬｉｆｅ Ｓｃｉｅｎｃｅｓ Ｒｅｓｅａｒｃｈ Ｐａｒｔｎｅｒｓ Ｖｚｗ 免疫原性ペプチドおよび免疫障害におけるその使用
EP2050814A1 (en) * 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
EP2623124A1 (en) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Elimination of immune responses to viral vectors
EP2244733B1 (en) 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
EP3075391A1 (en) 2008-02-14 2016-10-05 Life Sciences Research Partners VZW Strategies to prevent and/or treat immune responses to soluble allofactors
WO2009100505A1 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Immunogenic peptides and their use in transplantati
ES2676630T3 (es) 2008-02-14 2018-07-23 Life Sciences Research Partners Vzw Control inmunogénico de tumores y células tumorales
JP6173915B2 (ja) * 2010-11-25 2017-08-02 イムナテ・ソシエテ・ア・レスポンサビリテ・リミテＩｍｎａｔｅ Ｓａｒｌ 感染症、自己免疫疾患、同種因子に対する免疫応答、アレルギー性疾患、腫瘍、移植片拒絶反応、および、遺伝子療法または遺伝子ワクチン接種のために使用されるウイルスベクターに対する免疫応答の予防および／または治療における使用のための免疫原性ペプチド
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
WO2013164289A1 (en) * 2012-04-30 2013-11-07 Imcyse Sa Methods for induction of antigen-specific regulatory t cells

Also Published As

Publication number Publication date
JP6655626B2 (ja) 2020-02-26
CN107148427B (zh) 2021-08-13
EP3207053A1 (en) 2017-08-23
AU2015332621A1 (en) 2017-04-13
AU2015332621B2 (en) 2019-07-18
RU2709711C2 (ru) 2019-12-19
CN107148427A (zh) 2017-09-08
KR102556485B1 (ko) 2023-07-17
RU2017111657A (ru) 2018-11-19
RU2017111657A3 (pt) 2019-05-29
US20180228912A1 (en) 2018-08-16
MX2017004780A (es) 2017-11-30
GB201418433D0 (en) 2014-12-03
JP2018504419A (ja) 2018-02-15
AU2019250206A1 (en) 2019-11-07
EP3207053B1 (en) 2019-08-21
JP2020079271A (ja) 2020-05-28
KR20170069266A (ko) 2017-06-20
WO2016059236A1 (en) 2016-04-21
US20200397911A1 (en) 2020-12-24
CA2964426C (en) 2023-01-24
ES2751605T3 (es) 2020-04-01
PT3207053T (pt) 2019-11-15
CA2964426A1 (en) 2016-04-21
EP3636666A1 (en) 2020-04-15
PL3207053T3 (pl) 2020-05-18
DK3207053T3 (da) 2019-11-04

Similar Documents

Publication Publication Date Title
BR112017007773A2 (pt) novos peptídeos imunogênicos
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
EP3121175A4 (en) 1,3-benzodioxole derivative
CY1123622T1 (el) Τροποποιημενα μηνιγγιτιδοκοκκικα fhbp πολυπεπτιδια
BR112017009374A2 (pt) ?composições de ramnolipídeo de baixa viscosidade concentradas?
PH12017501863A1 (en) Bioconjugates and uses thereof
MX2018001793A (es) Compuestos para dispositivos opticamente activos.
EP3135668A4 (en) Novel disubstituted 1, 2, 4-triazine compound
MX2023006415A (es) Anticuerpos, usos y metodos.
WO2015107331A3 (en) Anti-light antibodies
UY4430S (es) “motocicleta”.
EP3464881A4 (en) ENERGY RECOVERY FROM MASS MOVEMENT OF MOVING FLUIDS.
ZA201902370B (en) Novel paratransgenic system for the biocontrol of disease-transmitting mosquitos
FR3026717B1 (fr) Atterrisseur d'aeronef.
BR112018012851A2 (pt) cepas de expressão de proteína melhoradas
FR3022984B1 (fr) Dispositif de reglage de l'inclinaison d'un reflecteur
FR3035582B1 (fr) Semelle de suceur d'aspirateur
FR3027015B1 (fr) Atterrisseur d'aeronef.
JP2015043197A5 (pt)
EP3700557A4 (en) DENDRITIC CELL VACCINE
IT201700123080A1 (it) Macchina per l'assemblaggio di dispositivi medicali.
IT201700035964A1 (it) “divisorio per boiserie”
ITUA20163609A1 (it) "micro-cogeneratore".
FR3016892B1 (fr) Dispositif de prechauffage d'un ensemble anodique.
FR3086176B1 (fr) Autoinjecteur.

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/74 (2006.01), A61K 47/00 (2006.01), C07K 1

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]